ONX 0801: Phase I started

Onyx began an open-label, dose-finding Phase I trial to evaluate intravenous ONX 0801 given as a 3-hour infusion on days 1, 8 and 15 of repeated 21-day cycles in about 60 patients. BTG granted Onyx ex...